Home » FDA Hands IBSA Farmaceutici 483 Over CAPAs, Procedures
FDA Hands IBSA Farmaceutici 483 Over CAPAs, Procedures
IBSA Farmaceutici did not open a corrective action, as required, for a trend in adverse events involving pain and/or swelling in the knee following injection of Sinovial or other sodium hyaluronate devices, according to a Form 483.
The GMP Letter
Devices Inspections and AuditsThe GMP Letter
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct